$43.11
2.82% today
Nasdaq, Apr 25, 04:17 pm CET
ISIN
NL0011606264
Symbol
MRUS
Sector
Industry

Merus N.V. Stock News

Neutral
GlobeNewsWire
2 days ago
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation
Positive
Seeking Alpha
18 days ago
Merus stands out in biotech with its innovative Biclonics and Multiclonics platforms, focusing on bispecific and multispecific antibodies, particularly petosemtamab. Strong financials with $724 million cash runway through 2028, allowing strategic R&D investments without immediate capital market pressures. Petosemtamab shows robust clinical data, receiving two FDA Breakthrough Therapy designatio...
Neutral
GlobeNewsWire
24 days ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 24th An...
Neutral
GlobeNewsWire
about 2 months ago
-  Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25
Neutral
GlobeNewsWire
about 2 months ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Neutral
GlobeNewsWire
2 months ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Neutral
GlobeNewsWire
2 months ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Neutral
GlobeNewsWire
3 months ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the New England Journal of Medicine (NEJM) published results of the registrational phase 2 eNRGy trial for Bize...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today